Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;30(2):165-177.
doi: 10.1016/j.thorsurg.2020.01.005.

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Bruna Pellini  1 , Jeffrey Szymanski  2 , Re-I Chin  2 , Paul A Jones  2 , Aadel A Chaudhuri  3
Affiliations
Review

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Bruna Pellini et al. Thorac Surg Clin. 2020 May.

Abstract

Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.

Keywords: Circulating tumor DNA (ctDNA); Liquid biopsy; Non-small cell lung cancer (NSCLC); Plasma genotyping.

PubMed Disclaimer

Conflict of interest statement

Disclosure A.A. Chaudhuri is a scientific advisor/consultant for Geneoscopy, Roche Sequencing Solutions and Tempus Labs; has received speaker honoraria and travel support from Varian Medical Systems, Roche Sequencing Solutions, and Foundation Medicine; receives research support from Roche Sequencing Solutions; and is an inventor of intellectual property licensed to Biocognitive Labs. The other authors have nothing to disclose.

MeSH terms